Drugs /

cd5/28zeta-expressing car-t cells

Back to Drugs List

Overview

NCI Definition [1]:
Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD5 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR), with potential immunomodulating and antineoplastic activities. Upon transfusion, the autologous CD5-specific CAR-28 zeta CAR T-cells are directed to and induce selective toxicity in CD5-expressing tumor cells. The tumor-associated antigen (TAA) CD5 is a T-cell surface glycoprotein expressed on the surface of normal T-cells, and is overexpressed on various B- and T-cell malignancies; its expression is associated with poor prognosis.

Clinical Trials

View Clinical Trials for cd5/28zeta-expressing car-t cells

Cd5/28zeta-expressing car-t cells has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating cd5/28zeta-expressing car-t cells, 1 is phase 1 (1 open).

CD5 Expression is the most frequent biomarker inclusion criterion for cd5/28zeta-expressing car-t cells clinical trials.

Adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, and enteropathy-associated T-cell lymphoma are the most common diseases being investigated in cd5/28zeta-expressing car-t cells clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cd5/28zeta-Expressing Car-T Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cd5/28zeta-expressing car-t cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cd5.car/28zeta car t cells, autologous cd5.car/28zeta car t cells, autologous cd5-specific car-28 zeta car t-lymphocytes, autologous cd5-specific car-28 zeta car t-cells, cd5 car t cells
NCIT ID [1]:
C148490

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.